BNP Paribas Financial Markets
CNTA

BNP Paribas Financial Markets’s Centessa Pharmaceuticals CNTA Stock Holding History

BNP Paribas Financial Markets’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,482
Closed -$98.6K – 5944
2026
Q1 		$98.6K Buy
2,482
+36
+1% +$921 ﹤0.01% 4384
2025
Q4 		$61.2K Buy
2,446
+1,248
+104% +$31.6K ﹤0.01% 4588
2025
Q3 		$29.1K Sell
1,198
-33,774
-97% -$600K ﹤0.01% 4809
2025
Q2 		$460K Buy
34,972
+33,854
+3,028% +$429K ﹤0.01% 3374
2025
Q1 		$16.1K Sell
1,118
-8,554
-88% -$140K ﹤0.01% 4595
2024
Q4 		$162K Buy
+9,672
New +$160K ﹤0.01% 3977

BNP Paribas Financial Markets's CNTA Position: Q2 2026 in Review

BNP Paribas Financial Markets sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 2,482 shares — an estimated $98.6K sold.

BNP Paribas Financial Markets first reported a position in CNTA in Q4 2024 and held it in 6 quarters. The position peaked at $460K in Q2 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • BNP Paribas Financial Markets reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,482 Centessa Pharmaceuticals shares in Q2 2026, an estimated $98.6K.
  • BNP Paribas Financial Markets first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • BNP Paribas Financial Markets's Centessa Pharmaceuticals position peaked at $460K in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.